iTeos Therapeutics (ITOS) said Thursday that it is deprioritizing inupadenant to "focus resources on other programs."
The company said it will present data from the dose escalation part of a a mid-stage trial evaluating inupadenant plus chemotherapy in non-small cell lung cancer at an event hosted by the European Society for Medical Oncology.
"While the initial signal for inupadenant's RP2D in the A2A-005 trial compared to chemotherapy alone is encouraging and supports its differentiated, insurmountable profile, we as well as our scientific and clinical advisory boards believe it does not meet sufficient level of clinical activity to warrant further investment," said iTeos chief executive officer Michel Detheux.
Detheux said the company will provide updates on its pipeline next year.
Shares of the company were up more than 2% in recent premarket activity.
Price: 8.50, Change: +0.20, Percent Change: +2.39
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。